Market Place
Sourcing Support
Ultimovacs ASA: Approval and publication of prospectus
28 Feb 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Cancellation of subsequent repair offering
13 Feb 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Q4 2024 Financial Results & Update
31 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to Q4 2024 results webcast presentation
27 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Extraordinary General Meeting held on Jan 9, 2025
09 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Notification of major holdings
09 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Announces Voting Rights Of Extraordinary Meeting
08 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs Discloses Voting Rights Of Extraordinary General Meeting
06 Jan 2025 //
GLOBENEWSWIRE
Regarding the extraordinary general meeting on 9 January 2025
05 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs: Notice of extraordinary general meeting on 9 Jan 2024
19 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Extraordinary General Meeting on 9 Jan 2024
19 Dec 2024 //
GLOBENEWSWIRE
ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY
18 Dec 2024 //
GLOBENEWSWIRE
Ultimovas Announces Business Merger with Zelluna Immunotherapy
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Mandatory notification of trade
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Announces Potential Subsequent Repair Offering
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs Reports Q2 2024 Results And Provides Business Update
21 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Notice of Resignation from Deputy Board Member
07 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs ASA announces revised terms of the employee share option program
24 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs provides update from Phase I study in malignant melanoma
11 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Ultimovacs to Present Poster at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs ASA “ Annual General Meeting held on April 18, 2024
18 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs AGM Voting Rights Disclosure
15 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs“ Invitation to Business Update on April 17, 2024
09 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
25 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
07 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs announces publication of results from NIPU Phase II trial with UV1
02 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results
14 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs Updates Timeline for Reporting on UV1 Phase II Trial INITIUM
16 Jan 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
28 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Share capital increase related to exercise of options
09 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Protocol Amendment in UV1 PII Study in Malignant Melanoma
31 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Webcast on the Results from Randomized UV1 Ph II NIPU Trial
25 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023
23 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs Announces NIPU Results Presented at ESMO 2023
17 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma
12 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial
27 Sep 2023 //
GLOBENEWSWIRE
Long survival spurs Ultimovacs to mull ways to end cancer trial
22 Aug 2023 //
FIERCE BIOTECH
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Trial of UV1
03 Aug 2023 //
GLOBENEWSWIRE
Ultimovacs™ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Award
22 Jun 2023 //
GLOBENEWSWIRE
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma
19 Jun 2023 //
GLOBENEWSWIRE
Ultimovacs provides updated guidance on timeline for readout of INITIUM
25 Apr 2023 //
GLOBENEWSWIRE
Ultimovacs ASA - Share Option Program
21 Apr 2023 //
GLOBENEWSWIRE
Ultimovacs ASA – Annual General Meeting held on 20 April 2023
20 Apr 2023 //
GLOBENEWSWIRE
Ultimovacs ASA Disclosure of voting rights of Annual General Meeting
14 Apr 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Annual Report 2022
24 Mar 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
24 Mar 2023 //
GLOBENEWSWIRE
Ultimovacs to Present at Cowen Healthcare Conference
27 Feb 2023 //
GLOBENEWSWIRE
Ultimovacs Reports Fourth Quarter 2022 Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
09 Feb 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Completed Patient Recruitment in NIPU PII Trial of UV1
23 Jan 2023 //
GLOBENEWSWIRE
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
20 Dec 2022 //
GLOBENEWSWIRE
Ultimovacs Completed Patient Recruitment in PI Trial in Prostate Cancer
14 Dec 2022 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insider
29 Nov 2022 //
GLOBENEWSWIRE
Ultimovacs ASA: New share capital registered
21 Nov 2022 //
GLOBENEWSWIRE
Ultimovacs ASA Reports 3Q 2022 Financial Results and Provides Update
10 Nov 2022 //
GLOBENEWSWIRE
Ultimovacs Announces First Patient Randomized in PII LUNGVAC Trial of UV1
25 Oct 2022 //
GLOBENEWSWIRE
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy
17 Oct 2022 //
GLOBENEWSWIRE
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate
05 Oct 2022 //
GLOBENEWSWIRE
